PLEKHA6

Across TCGA pan-cancer cohorts, PLEKHA6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLEKHA6 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLEKHA6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLEKHA6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where PLEKHA6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.592	0.301	<.001	76	view →
CCRCC	OS	Tertile	All	0.943	0.713	.003	39	view →
UCEC	OS	Median	All	1.000	0.847	.004	24	view →
LUAD	OS	Tertile	III,IV	0.737	0.268	.027	5	view →
LSCC	DFS	Median	II,III,IV	0.863	0.965	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLEKHA6–PDAC (DFS)

Open the PDAC breakdown →